Novel antibody reduces tumor growth in treatment-resistant breast and ovarian cancers
Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...
News-Medical.Net on MSN8d
Breakthrough study defines ideal interval for immunotherapy and liver transplants
Hepatocellular carcinoma (HCC) represents about 80 to 90% of cases of primary liver cancer. On a global level, 905,700 new cases and 830,200 deaths were registered in 2020 according to the World ...
News Medical on MSN22d
Vimseltinib Approved by FDA for Tenosynovial Giant Cell Tumor
The investigators reported that 67% of patients receiving vimseltinib had measurably reduced tumor volume, compared with none in the placebo group. Additionally, patients in the trial who received ...
Nature1mon
Human Tumor Atlas Network
The Human Tumor Atlas Network leverages scientific collaboration to integrate samples, analytical modalities and tools into detailed atlases of tumor evolution. Expanding our spatial understanding ...
mskcc.org24d
FDA Approves Vimseltinib for Tenosynovial Giant Cell Tumor (TGCT)
The investigators reported that 67% of patients receiving vimseltinib had measurably reduced tumor volume, compared with none in the placebo group. Additionally, patients in the trial who received ...